A 28-year-old female with a 4-year history of opioid use disorder (heroin and pharmaceutical opioids) presents to the outpatient clinic for maintenance therapy. She has been abstinent for 3 months following a residential de-addiction programme and wishes to continue treatment to prevent relapse. She is currently on no medications. On examination, she is alert, cooperative, and denies active withdrawal symptoms. Her liver function tests are normal, and she is HIV-negative. She is concerned about the risk of overdose if she relapses while on maintenance therapy. Which medication is most appropriate for her long-term management?

Explanation

## Long-Term Pharmacotherapy for Opioid Use Disorder: Relapse Prevention ### Clinical Context The patient is: - **Abstinent for 3 months** (post-acute withdrawal phase) - **Motivated** (sought treatment, completed residential programme) - **Concerned about overdose risk** (key clinical clue) - **Medically stable** (normal LFTs, HIV-negative) This is a scenario where **opioid antagonist therapy** (naltrexone) becomes appropriate, whereas in acute withdrawal (Question 1), opioid agonists are mandatory. ### Pharmacotherapy Options in OUD | Medication | Class | Mechanism | Onset | Relapse Prevention | Overdose Risk | Adherence | |------------|-------|-----------|-------|-------------------|---------------|----------| | **Methadone** | Full μ-agonist | Receptor occupancy | Slow (days) | Excellent | High if missed doses | Requires daily clinic visits | | **Buprenorphine** | Partial μ-agonist | Partial receptor occupancy | Fast (hours) | Excellent | Low (ceiling effect) | Flexible (office-based) | | **Naltrexone (oral)** | μ-antagonist | Blocks opioid receptors | 1 hour | Moderate (requires motivation) | **Zero** (blocks euphoria) | Poor (daily dosing) | | **Naltrexone (ER, Vivitrol)** | μ-antagonist | Blocks opioid receptors | 24–72 hours | Excellent | **Zero** (blocks euphoria) | **Excellent** (monthly IM) | | **Acamprosate** | GABA modulator | Restores glutamate balance | Days | Used in alcohol use disorder, NOT opioids | N/A | Not indicated | **Key Point:** The patient's explicit concern about overdose risk is the clinical clue that she is an ideal candidate for naltrexone. Unlike agonist therapies (methadone, buprenorphine), naltrexone completely blocks opioid euphoria, eliminating overdose risk if she relapses. ### Why Extended-Release Naltrexone (Vivitrol) is Correct **High-Yield:** Extended-release naltrexone (naltrexone ER, Vivitrol) is a monthly intramuscular injection that provides: 1. **Zero overdose risk:** Naltrexone is a pure μ-opioid antagonist. If the patient uses opioids while on naltrexone, the drug blocks all opioid effects, preventing euphoria and respiratory depression. This directly addresses her concern. 2. **Excellent adherence:** Monthly IM dosing eliminates the burden of daily oral medication, a major cause of treatment dropout. 3. **Sustained receptor blockade:** The ER formulation maintains therapeutic antagonist levels for 30 days, preventing impulsive relapse. 4. **Ideal for motivated patients:** She has demonstrated motivation (3-month abstinence, completed residential treatment), making her an ideal candidate for naltrexone, which requires high intrinsic motivation to maintain. 5. **No abuse potential:** Unlike methadone and buprenorphine (which are opioid agonists and can be diverted/misused), naltrexone has zero abuse potential. ### Naltrexone Mechanism & Pharmacology ```mermaid flowchart TD A["Opioid relapse attempt"]:::urgent --> B["Opioid binds to μ-receptor"]:::outcome B --> C{"Naltrexone present?"}:::decision C -->|"No (off naltrexone)"| D["Opioid activates receptor"]:::outcome D --> E["Euphoria + respiratory depression"]:::urgent E --> F["Risk of overdose death"]:::urgent C -->|"Yes (on naltrexone ER)"| G["Naltrexone competitively blocks opioid"]:::action G --> H["No opioid effect"]:::action H --> I["No euphoria, no respiratory depression"]:::outcome I --> J["Overdose risk = ZERO"]:::outcome ``` ### Treatment Selection Algorithm ```mermaid flowchart TD A["Opioid Use Disorder"]:::outcome --> B{"Clinical phase?"}:::decision B -->|"Acute withdrawal (0–7 days)"| C["Buprenorphine or Methadone"]:::action B -->|"Stabilization (weeks 1–4)"| D["Continue agonist, titrate to maintenance"]:::action B -->|"Maintenance (> 1 month abstinent)"|E{"Patient preference & motivation?"}:::decision E -->|"Wants agonist therapy"| F["Buprenorphine or Methadone"]:::action E -->|"Wants antagonist (zero overdose risk)"| G{"Adherence capacity?"}:::decision G -->|"High motivation, can do monthly IM"| H["Naltrexone ER (Vivitrol)"]:::action G -->|"Prefers oral daily"| I["Naltrexone 50 mg oral daily"]:::action E -->|"Concerned about relapse to alcohol too"| J["Consider acamprosate (alcohol) + naltrexone (opioid)"]:::action ``` **Clinical Pearl:** Naltrexone is often underutilized in opioid use disorder because it requires higher patient motivation and has lower relapse-prevention efficacy than agonists in poorly motivated patients. However, in motivated patients like this one, it offers unique advantages: zero overdose risk and zero abuse potential. ### Comparison: Oral Naltrexone vs. Extended-Release Naltrexone | Feature | Oral Naltrexone 50 mg daily | Naltrexone ER (Vivitrol) 380 mg IM monthly | |---------|------------------------------|-------------------------------------------| | **Adherence** | Poor (daily dosing, high dropout) | Excellent (monthly IM, directly observed) | | **Relapse prevention** | Moderate (depends on daily compliance) | Excellent (sustained 30-day blockade) | | **Overdose risk** | Zero | Zero | | **Cost** | Lower | Higher | | **Ideal for** | Highly motivated, stable patients | Motivated patients with adherence concerns | **Mnemonic:** **VIVITROL = Very Ideal for Vigilant Individuals Trying to Resist Opioid Lapse** (monthly IM, zero overdose, blocks euphoria, requires motivation).